ALBERT DAVID LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,192 INR | +1.75% |
|
+5.97% | +22.26% |
| 31/03 | Albert David Limited Announces Board Retirement | CI |
| 14/03 | Albert David Limited Announces Management Changes | CI |
| Sales 2022 | 3.14B 37.6M | Sales 2023 | 3.42B 40.97M | Capitalization | 2.92B 35.04M |
|---|---|---|---|---|---|
| Net income 2022 | 353M 4.23M | Net income 2023 | 362M 4.34M | EV / Sales 2022 | 0.43 x |
| Net cash position 2022 | 1.69B 20.29M | Net cash position 2023 | 1.98B 23.74M | EV / Sales 2023 | 0.28 x |
| P/E ratio 2022 |
8.61
x | P/E ratio 2023 |
8.08
x | Employees | 1,271 |
| Yield 2022 |
1.69% | Yield 2023 |
1.76% | Free-Float | 35.79% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.75% | ||
| 1 week | +5.97% | ||
| Current month | +10.67% | ||
| 1 month | +11.72% | ||
| 3 months | -22.16% | ||
| 6 months | +49.16% | ||
| Current year | +22.26% |
1 week
1 150.00
1 218.65
1 month
1 046.151 234.00
Current year
961.001 607.90
1 year
554.501 607.90
3 years
432.001 607.90
5 years
263.001 607.90
10 years
263.001 607.90
| Managers | Title | Age | Since |
|---|---|---|---|
Umesh Kunte
CEO | Chief Executive Officer | 55 | 06/23/06 |
| Director of Finance/CFO | - | 01/20/01 | |
| Chairman | 70 | 20/88/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 20/88/20 | |
| Director/Board Member | 66 | 31/14/31 | |
| Director/Board Member | - | 11/22/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,192 | +1.75% | 6,777 |
| 25/24/25 | 1,172 | -1.83% | 4,421 |
| 24/24/24 | 1,194 | -0.36% | 4,527 |
| 23/24/23 | 1,198 | +1.00% | 6,403 |
| 22/24/22 | 1,186 | +5.42% | 8,644 |
Delayed Quote NSE India S.E., April 26, 2024 at 05:13 pm IST
More quotes
Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- ALBERTDAVD Stock
- ALBERTDAVD Stock
